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Aims Atrial fibrillation (AF) risk factors translate into disease progression. Whether this affects women and men differ-





The Rate Control Efficacy in Permanent Atrial Fibrillation (RACE II) randomized 614 patients, 211 women and 403
men, to lenient or strict rate control. In this post hoc analysis risk factors, cardiovascular events during 3-year
follow-up (cardiovascular death, heart failure hospitalization, stroke, systemic embolism, bleeding, and life-
threatening arrhythmic events), outcome parameters, and QoL were compared between the sexes. Women were
older (71 ± 7 vs. 66 ± 8 years, P < 0.001), had more hypertension (70 vs. 57%, P = 0.002), and heart failure with pre-
served ejection fraction (36 vs. 17%, P < 0.001), but less coronary artery disease (13 vs. 21%, P = 0.02). Women
had more risk factors (3.7 ± 1.2 vs. 2.9 ± 1.4, P < 0.001) Cardiovascular events occurred in 46 (22%) women and 59
(15%) men (P = 0.03). Women had a 1.52 times [95% confidence interval (CI) 1.03–2.24] higher yearly cardiovascu-
lar event-rate [8.2% (6.0–10.9) vs. 5.4% (4.1–6.9), P = 0.03], but this was no longer significant after adjusting for the
number of underlying risk factors. Women had reduced QoL, irrespective of age and heart rate but negatively
influenced by their risk factors.
...................................................................................................................................................................................................
Conclusion In this permanent AF population, women had more accumulation of AF risk factors than men. The observed higher
cardiovascular event rate in women was no longer significant after adjusting for the number of risk factors. Further,
QoL was negatively influenced by the higher number of risk factors in women. This suggests that sex differences
may be driven by the greater risk factor burden in women.
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Introduction
Atrial fibrillation (AF) is a major health burden worldwide.1 Whilst
women remain underrepresented in randomized clinical trials
(RCTs), there has been an accumulation of evidence on sex-specific
differences in incidence, prevalence, risk factors, presentation, and
outcomes of patients with AF.2–4 Women are generally older, more
often have hypertension, but less often have coronary heart dis-
ease.2–4 Risk factors may translate into AF development, in patients
with metabolic syndrome a higher number of risk factors is associ-
ated with a stepwise increase in AF risk and poorer outcomes.4,5
Whether this affects women and men differently is unclear. Registry
studies have reported a higher incidence of AF-related stroke and
systemic thromboembolism specifically in older women.6,7 Increased
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mortality risk in women has also been described, but results are in-
consistent.8,9 Furthermore, women with AF are generally more
symptomatic, seek more care for symptoms, and report a lower qual-
ity of life (QoL).10 Questions on sex-specific differences in AF remain,
and data on predictors of outcome is scarce to non-existent.
Gaps in knowledge on sex differences are undesirable since recog-
nition of sex-based differences may offer an opportunity to improve
personalized treatments. The aim of this Rate Control Efficacy in
Permanent AF: A Comparison between Lenient vs. Strict Rate
Control II (RACE II)11 post hoc analysis was to investigate sex-




RACE II was a randomized, multicentre study comparing long-term
effects of lenient vs. strict rate control in 614 patients with permanent AF
performed in The Netherlands between January 2005 and June 2007.
Eligibility criteria were: permanent AF for up to 12 months, age <_80 years,
mean resting heart rate >80 b.p.m., and current use of oral anticoagula-
tion therapy [Vitamin K antagonists or aspirin, if no risk factors for throm-
boembolic complications were present according to European Society of
Cardiology (ESC) AF guidelines at the time of inclusion].12 Previous
stroke, but not transient ischemic attacks, was an exclusion criteria. Study
design details have been described before.11 Patients randomized to le-
nient rate control had a resting heart rate target <110 b.p.m. Patients ran-
domized to strict rate control had two heart rate targets: a resting heart
rate target <80 b.p.m. and a heart rate target during moderate exercise
<110 b.p.m. Patients were administered one or more negative dromo-
tropic drugs until target(s) were reached. After achievement of rest and
activity heart rate targets in the strict group, 24-h Holter monitoring was
performed to check for bradycardia. Follow-up outpatient visits occurred
every 2 weeks until heart rate target(s) were achieved (dose adjustment
phase), and in all patients after 1, 2, and 3 years. Follow-up was terminated
after 3 years or on 30 June 2009, whichever came first. The institutional
review board of each participating hospital approved the study, and all
patients provided written informed consent. For the present analysis,
sex-differences in risk factors, cardiovascular events and associated
parameters, as well as QoL were assessed.
Atrial fibrillation risk factors
Many risk factors are known to be associated with AF.2–4,12 In RACE II,
extensive patient characteristics were collected and for each individual
patient the number of AF risk factors was determined. Risk factors in-
cluded: hypertension (1 point); heart failure with reduced ejection frac-
tion (HFrEF) or heart failure with preserved ejection fraction (HFpEF) (1
point); advanced age: >65 years (1 point); diabetes mellitus (1 point);
coronary artery disease (CAD) (1 point); overweight or obesity: body
mass index (BMI) >25 kg/m2 (1 point); kidney dysfunction: estimated glo-
merular filtration rate (eGFR) <60 mL/min/1.73m2 (1 point); and moder-
ate to severe mitral valve insufficiency (grade >_2) (1 point) (Table 2).
Estimated glomerular filtration rate was calculated using MDRD formula:
175  [serum creatinine (mmol/L)  0.0113]1.154  age (years)0.203
(0.742 if female).
Blood markers
After inclusion 10 mL blood was collected by vein puncture. Within 1 h
the EDTA tube was centrifuged for 10 min, plasma was removed, and lo-
cally stored at 80 . After study completion NT-proBNP and
hsTroponin-T measurements were performed using electrochemilumini-
secent immunoassays (Roche Modular E170, Roche Diagnostics,
Mannheim, Germany) at the core laboratory of the University Medical
Center Groningen. Overall machine day-to-day variation was 2.0–2.2%.
Echocardiography
Two-dimensional transthoracic echocardiography was performed at baseline
in left lateral decubitus position. Images were obtained from parasternal
(long- and short axis) and apical (two- and four-chamber) views. Atrial and
ventricular dimensions and ejection fraction (LVEF) were quantified accord-
ing to standard guideline recommendations. Left atrial volume was measured
using the biplane Simpson method and indexed (LAVI) to the body surface
area. Body surface area was calculated using the formula of DuBois and
DuBois: (weight (kg)0.425 height (cm)0.725) 0.007184. Presence of HFrEF
and HFpEF was determined using following respective definitions: HFrEF:
LVEF< 40%; HFpEF: dyspnoea and/or fatigue, LVEF >_ 40%, NT-proBNP
>900pg/mL, and structural heart disease classified as LAVI >_34mL/m2 and/
or left ventricular mass index >_95g/m2 in women and >_115g/m2 in men.13
Cardiovascular events
Cardiovascular events included cardiovascular death, hospitalization for
heart failure, stroke, systemic embolism, major bleeding, or arrhythmic
events, including syncope, sustained ventricular tachycardia, cardiac ar-
rest, life-threatening adverse effects of rate-control drugs, and pacemaker
or cardioverter-defibrillator implantation. Extensive definitions of individ-
ual composites have been previously described.11 Cardiovascular events
that occurred between randomization and end of study were recorded.
An endpoint adjudication committee, who were unaware of assigned
treatment strategy, adjudicated endpoints. Minimal follow-up was 2 years;
median follow-up was 3 years (interquartile range 2.2–3.1 years).
Quality of life
Baseline and end-of-study QoL was measured using three questionnaires.
The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36)
assessed General Health. SF-36, a validated general health survey that is
frequently in arrhythmia studies, contains items to assess physical- and
mental health. The survey is composed of eight subscales of multiple-
choice questions, ranging in a stepwise fashion from impaired/low QoL to
What’s new?
• Women with permanent atrial fibrillation (AF) had more accu-
mulation of AF risk factors than men.
• In women, a higher cardiovascular event rate was observed,
this was no longer significant after adjusting for the number of
risk factors. Quality of life was negatively influenced by the
higher number of risk factors in women.
• These findings support and extend previous findings and fur-
ther underscore the evidence that women with AF show
many differences in clinical presentation and outcome events
compared to men.
• Sex differences deserve attention, not in the least to character-
ize and determine their role so that our assessment and treat-
ment of patients has a foundation that incorporates these
differences if necessary.
• Focusing on the underlying risk factor burden may provide a
mechanical and biological basis to better understand the sex-
related differences in the underlying substrate and associated
cardiovascular risk in patients with AF.





















Age (years), mean ± SD 68 ± 8 71 ± 7 66 ± 8 <0.001
Total AF durationa (months), median (IQR) 18 (6–60) 18 (3–59) 18 (5–60) 0.90
Duration AF episode at inclusion (months), median (IQR) 3 (1–6) 3 (1–7) 3 (1–5) 0.20
Medical history, n (%)
Cardiomyopathy 41 (7) 7 (3) 34 (8) 0.02
Respiratory disease 104 (17) 31 (15) 73 (18) 0.31
Previous hospitalization for heart failure 60 (10) 22 (10) 38 (9) 0.78
Thromboembolic complication 72 (12) 29 (14) 43 (11) 0.29
Physical examination, mean ± SD
Length (cm) 174 ± 9 166 ± 7 178 ± 7 <0.001
Weight (kg) 87 ± 17 79 ± 15 91 ± 16 <0.001
Body mass index (kg/m2) 28.6 ± 4.6 28.7 ± 4.8 28.6 ± 4.4 0.94
Blood pressure (mmHg)
Systolic 136 ± 18 138 ± 18 135 ± 18 0.02
Diastolic 83 ± 11 84 ± 11 83 ± 11 0.18
Heart rate in rest (b.p.m.) 96 ± 12 96 ± 13 96 ± 12 0.97
Clinical status
Treatment, n (%)
Strict rate control 303 (49) 105 (50) 198 (49) 0.93
Lenient rate control 311 (51) 106 (50) 205 (51)
CHADS2 score
Mean ± SD 1.4 ± 1.1 1.6 ± 1.1 1.3 ± 1.0 <0.001
0 or 1, n (%) 373 (61) 107 (51) 266 (66) <0.001
2, n (%) 159 (26) 67 (32) 92 (23) 0.02
3–6, n (%) 82 (13) 37 (18) 45 (11) 0.03
Symptoms, n (%) 348 (57) 147 (70) 201 (50) <0.001
Palpitations 145 (24) 77 (37) 68 (17) 0.001
Dyspnoea 215 (35) 94 (45) 122 (30) 0.54
Fatigue 183 (30) 81 (38) 102 (25) 0.42
Functional class (NYHA)—I/II/III (%) 65/30/5 56/37/7 70/27/3 0.003
eGFR (mL/min/1.73 m2) 65 ± 16 61 ± 16 68 ± 16 <0.001
Treatments
Previous ECV, n, median (range) 1 (0–22) 1 (0–8) 1 (0–22) 0.57
Rate control medication, n (%)
No rate control drugs 63 (10) 10 (5) 53 (13) 0.001
Beta-blocker 408 (66) 154 (73) 254 (63) 0.02
Verapamil or diltiazem 90 (15) 30 (14) 60 (15) 0.91
Digoxin 198 (32) 94 (45) 104 (26) <0.001
Other medication at baseline, n (%)
ACE-inhibitors 203 (33) 68 (32) 135 (34) 0.79
Angiotensin receptor blockers 114 (19) 48 (23) 66 (16) 0.06
ACE-inhibitors and/or ARB 306 (50) 114 (54) 192 (48) 0.15
Diuretics 247 (40) 104 (49) 143 (36) 0.001
Statin 177 (29) 57 (27) 120 (30) 0.51
Vitamin K antagonists 606 (99) 209 (99) 397 (99) 0.72
Laboratory values, median (IQR)
NT-proBNP (pg/mL) 1003 (634–1632) 1240 (889–1907) 879 (544–1408) <0.001
hsTroponin-T (pg/mL) 9 (7–14) 9 (6–13) 9 (7–14) 0.22
Echocardiographic parameters
Left atrial end systolic volume (mL) 73 ± 26 69 ± 23 75 ± 27 0.02
Continued
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not impaired/high QoL. Subscales are transformed to a score ranging
from 0 to 100, with lower scores representing a lower QoL. Severity of
AF-related symptoms was assessed using the University of Toronto AF
Severity Scale (AFSS), an instrument intended to measure perception of
arrhythmia-related symptom severity. This 7-item questionnaire includes
common AF symptoms (e.g. palpitations, dyspnoea). Items are rated on a
6-point scale. The final score ranges from 0 to 35, with a higher score indi-
cating greater AF symptom severity. Severity of fatigue was measured us-
ing the Multidimensional Fatigue Inventory-20 (MFI-20). MFI-20 contains
20 statements covering five domains of fatigue: general-, physical- and
mental fatigue, and reduced activity and motivation. Scores range from 4
to 20, with higher scores indicating more fatigue.
Statistical analysis
For the purpose of this post hoc analysis, the RACE II cohort population
was stratified and analysed by sex. Baseline characteristics were com-
pared between men and women. Variables are presented as numbers
(percentage) or means (± standard deviation), as appropriate.
Continuous variables were tested for normal distribution by the
Kolmogorov–Smirnov test. Comparisons between continuous variables
were performed using the Wilcoxon rank-sum test or two-sample t-test
depending on normality; comparisons between nominal variables were
performed using the Pearson’s v2 test or Fisher’s exact test, depending
on expected cell sizes. Yearly event-rates were calculated by dividing the
number of cardiovascular events by the number of follow-up years.
Individual patient years were calculated as the time from randomization
until the moment of censoring. Patients were censored if they withdrew
informed consent, died, were lost to follow-up, had been followed
through 30 June 2009, or had been in the trial for the maximum of
3 years. Differences in yearly event-rates were calculated by MedCalc
(Windows version: 17.6). Cox regression analysis was performed to de-
termine covariates associated to cardiovascular event occurrence for the
total population and women and men specifically. Predefined univariate
parameters with P < 0.1 and randomization strategy were tested in a mul-
tivariate Cox proportional hazards model using a backward stepwise ap-
proach according to likelihood ratio. Final multivariable models included
all covariates with P < 0.05 and randomization strategy to adjust for the
post hoc nature of the current analysis. Final models were tested for first-
line interactions. ANOVA was used to look for differences in QoL scores
after adjusting for age, heart rate, and risk factors (since lower heart rates
may reduce exercise capacity and induce fatigue).
Because of significant imbalances in baseline characteristics between
women and men, we performed sensitivity analysis using propensity
score matching in order to compare outcomes and QoL between
matched women and men. Propensity scores were calculated for each
patient using multivariable logistic regression based upon the following
covariates: age, systolic blood pressure, BMI, estimated glomerular filtra-
tion rate, presence of diabetes, LVEF, NT-proBNP levels, and randomiza-
tion strategy. Women and men were matched in a 1:1 ratio without
replacement within 0.001 units of the propensity score.
All tests of significance were two-sided, with P-values of <0.05 as-
sumed to indicate significance. All the analyses were considered to be ex-
ploratory. Analyses were generated by using SPSS version 23.0 for
Windows (IBM Corp, Chicago, IL, USA).
Results
Patient characteristics and atrial
fibrillation risk factors
RACE II included 211 women and 403 men. Women were older
(71 ± 7 vs. 66 ± 8, P < 0.001), 36% of women were >_75 years com-
pared to 20% of men. Women had more hypertension (70% vs. 57%,
P = 0.002), HFpEF (36% vs. 17%, P < 0.001), and mitral valve regurgita-
tion (27% vs. 13%, P < 0.001), but less CAD (13% vs. 21%, P = 0.02)
(Tables 1 and 2). Renal function was worse in women (eGFR
61 ± 16 mL/min/1.73 m2 vs. 68 ± 16 mL/min/1.73 m2, P < 0.001). This
resulted in higher CHADS2 scores (1.6± 1.1 vs. 1.3 ± 1.0, P < 0.001)
and more AF risk factors (3.7 ± 1.2 in women vs. 2.9 ± 1.4 in men,
P < 0.001, Table 2, Figure 1). Left ventricular dimensions were smaller
in women but baseline LAVI did not differ (Table 1). NT-proBNP lev-
els were higher in women (1240 pg/mL vs. 879 pg/mL, P < 0.001).
Rate control
Baseline heart rates were similar (Table 1). At baseline, women more
frequently used rate control drugs (often digoxin, or digoxin in combi-
nation with a beta-blocker). This persisted through follow-up (Table 1,
Supplementary material online, Table S1). After dose-adjustment,
women in the lenient group used a higher dose of beta-blockers (all
doses were normalized to metoprolol equivalent doses) compared to
men (135± 84 mg vs. 112± 73 mg, P = 0.04). Women with both lenient
and strict rate control used lower doses of digoxin compared to men
(for lenient 169± 66mg vs. 201± 81mg, P = 0.034; for strict 189± 82mg
vs. 211± 83mg, P = 0.04). This persisted till the end of follow-up. There
were no sex differences in heart rate in the lenient and strict rate










Left atrial volume index (mL/m2) 36 ± 12 37 ± 12 36 ± 12 0.30
Right atrial length, apical view (mm) 58 ± 8 57 ± 8 59 ± 8 0.01
Left ventricular end diastolic dimension (mL) 51 ± 7 48 ± 7 53 ± 7 <0.001
Left ventricular end systolic dimension (mL) 36 ± 8 33 ± 8 38 ± 8 <0.001
Left ventricular mass index (g/m2) 135 ± 44 123 ± 39 142 ± 45 <0.001
Left ventricular ejection fraction (%) 52 ± 12 54 ± 12 51 ± 12 0.002
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ECV, electrical cardioversion; eGFR, estimated glomerular filtration rate; IQR,
interquartile range; NT-proBNP, N-terminal proB-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation.
aTotal AF duration denotes the time from diagnosis of AF to start of study.












During 3-year follow-up (interquartile range 2.2–3.1 years), 105
(17%) cardiovascular events occurred, 46 (22%) in women and 59
(15%) in men (Table 3). Yearly cardiovascular event-rate was 6.3%/
year [95% confidence interval (CI) 5.2–7.7]. Women had a 1.52
(1.03–2.24) times higher yearly event-rate: 8.2%/year (95% CI 6.0–
10.9) in women vs. 5.4%/year (95% CI 4.1–6.9) in men, P = 0.03. After
adjusting for age it remained significant, P = 0.04. It was no longer sig-
nificant after adjusting for the number of risk factors (P = 0.16).
Additionally, in women and men no significant difference in primary
outcome between lenient and strict rate control was observed, re-
spectively P = 0.31 and P = 0.89. In the propensity-score matched
....................................................................................................................................................................................................................
Table 2 AF risk factors
AF risk factors, n (%) Overall Women Men P-value
Hypertension 375 (61) 147 (70) 228 (57) 0.002
Heart failure
HFrEF 93 (15) 25 (12) 68 (17) 0.10
HFpEFa 100 (23) 52 (36) 48 (17) <0.001
Advanced age (years) <0.001
65–74 258 (42) 101 (48) 157 (39)
>_75 155 (25) 76 (36) 79 (20)
Diabetes mellitus 70 (11) 30 (14) 38 (9) 0.08
Coronary artery disease 111 (18) 28 (13) 83 (21) 0.02
Obesity 0.34
BMI >25–30 kg/m2 289 (47) 91 (43) 198 (49)
BMI >30 kg/m2 189 (31) 68 (32) 121 (30)
Kidney dysfunction 229 (37) 110 (52) 119 (30) <0.001
eGFR <60 mL/min/1.73 m2
Mitral regurgitation 110 (18) 56 (27) 54 (13) <0.001
Number of AF risk factorsb, mean ± SD 3.2±1.4 3.7±1.2 2.9±1.4 <0.001
AF, atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction; SD, standard deviation.
aN = 436 had data on all variables that compose HFpEF (146 women and 290 men).
bFor description see methods section: Atrial fibrillation risk factors.
Cardiovascular event ratea
Quality of life
Sex differences may be driven by the
greater risk factor burden in women





Figure 1 Sex differences in risk factors. In the RACE II population, consisting of patients with permanent AF, women had more accumulation of AF
risk factors than men. aThe observed higher cardiovascular event rate in women was no longer significant after adjusting for the number of risk fac-
tors. Further, QoL was negatively influenced by the higher number of risk factors in women. This suggests that sex differences may be driven by the
greater risk factor burden in women. Colours in the left panel (men blue, women red) represent the distribution of risk factors in the RACE II
population.
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cohort also no differences in outcome between women and men
were observed (Supplementary material online, Tables S2 and S3).
Parameters associated with
cardiovascular event occurrence
In multivariable analysis, AF duration [hazard ratio (HR) 1.01 per month
(95% CI 1.00–1.01), P= 0.004), female sex [HR 1.87 (95% CI 1.15–3.03),
P= 0.011], NT-proBNP [HR 1.03 per 100 (95% CI 1.01–1.04),
P= 0.001], and hsTroponin-T [HR 1.02 per 1 (95% CI 1.01–1.04),
P= 0.003] were associated with the occurrence of cardiovascular events
in the total population (Table 4). In women, LAVI [HR 1.09 per 1 mL/m2
(95% CI 1.05–1.14), P< 0.001] and AF duration [HR 1.03 per month
(95% CI 1.01–1.04), P< 0.001] were associated with outcome; in men,
NT-proBNP [HR 1.08 per 100 (95% CI 1.03–1.13), P< 0.001] and
hsTroponin-T [HR 1.09 per 1 (95% CI 1.04–1.13), P < 0.001]. There
were interactions between LAVI and AF duration (P= 0.03) and NT-
proBNP and hsTroponin-T (P= 0.02) in women and men, respectively.
Symptoms and quality of life
Women had more symptoms (70% vs. 50%, P < 0.001), Table 1). At
the end of follow-up, 42% of men and 53% of women had symptoms
(P = 0.004): dyspnoea (25% vs. 38%, P = 0.03), fatigue (20% vs. 31%,
P = 0.15), and palpitations (5% vs. 20%, P < 0.001) were more frequent
in women. Quality of life, as assessed with SF-36, MFI-20, and AFSS
was significantly lower in women, also after correcting for heart rate,
age, and number of risk factors (Figure 2). This remained unchanged
during follow-up. Differences in physical functioning and fatigue scales
were most pronounced. Emotional limitations (SF-36) and mental fa-
tigue (MFI-20) did not differ between the sexes. Similar results were
observed in the matched cohort (Supplementary material online,
Table S4) The number of AF risk factors was associated with a reduced
QoL, more clearly in women than in men, this suggests that women
are more negatively affected, in terms of QoL, by permanent AF; per
risk factor baseline SF-36 physical score decreased by 1.40 in women
(95% CI 2.68 to 0.46) and by 1.21 in men (95% CI 1.90 to
0.54), both P < 0.05. This was also true for MFI-20 scales with the
exception of mental fatigue. The number of risk factors was not a pre-
dictor for SF-36 mental scores or AFSS in both sexes.11
Discussion
We show that men and women with permanent AF are not the same.
Women were older, had more AF risk factors, and more frequently
used rate control drugs. In women and men different parameters were
associated with events. The observed higher cardiovascular event rate
in women was no longer significant after adjusting for the number of
risk factors. Further, QoL was negatively influenced by the higher num-
ber of risk factors in women. These results suggest that sex differences
may be mainly driven by the presence of more risk factors in women
Patient characteristics and atrial
fibrillation risk factors
In line with published data, we describe different patient characteris-
tics in women and men.2–4 Women were older and more likely to
....................................................................................................................................................................................................................
Table 3 Cardiovascular events during follow-up
Overall Women Men P-value
Yearly cardiovascular event-rate (%) (95% CI) 6.3 (5.2–7.7) 8.2 (6.0–10.9) 5.4 (4.1–6.9) 0.03
Total cardiovascular eventsa, n (%) 105 (17.1) 46 (21.8) 59 (14.6) 0.03
Death from cardiovascular cause 20 (3.3) 9 (4.3) 11 (2.7) 0.34
Cardiac arrhythmic death 7 (1.1) 4 (1.9) 3 (0.7) 0.24
Cardiac non-arrhythmic death 3 (0.5) 1 (0.5) 2 (0.5) 0.99
Non-cardiac vascular death 10 (1.6) 4 (1.9) 6 (1.5) 0.74
Heart failure hospitalization 22 (3.6) 9 (4.3) 13 (3.2) 0.50
Stroke 15 (2.4) 5 (2.4) 10 (2.5) 0.99
Ischaemic stroke 11 (1.8) 4 (1.9) 7 (1.7) 0.99
Haemorrhagic stroke 5 (0.8) 1 (0.5) 4 (1.0) 0.67
Systemic embolism 1 (0.2) – 1 (0.2) 0.99
Bleeding 28 (4.6) 14 (6.6) 14 (3.5) 0.10
Intracranial bleeding 3 (0.5) 1 (0.5) 2 (0.5) 0.99
Extracranial bleedingb 25 (4.1) 13 (6.2) 12 (3.0) 0.08
Syncope 6 (1.0) 4 (1.9) 2 (0.5) 0.19
Life-threatening adverse effects of rate control drugs 5 (0.8) 3 (1.4) 2 (0.5) 0.35
Sustained ventricular tachycardia or ventricular fibrillation 1 (0.2) – 1 (0.2) 0.99
Implantable cardioverter defibrillation implantation 1 (0.2) – 1 (0.2) 0.99
Pacemaker implantation 6 (1.0) 2 (0.9) 4 (1.0) 0.99
CI, confidence interval.
aIncludes the total number of cardiovascular events that occurred during follow-up.
bExtracranial bleeding events in women included: gastrointestinal (n = 4), post-surgery/intervention (n = 3), knee haematoma (n = 2), large haematoma upper leg after trauma
(n = 3), retroperitoneal (n = 1). Extracranial bleeding events in men included: gastrointestinal (n = 5), post-surgery/intervention (n = 4), retroperitoneal bleeding (n = 1), urinary
tract (n = 1), pulmonary related to bronchus carcinoma (n = 1).













Table 4 Multivariable Cox regression analyses
Overall Women Men
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Lenient rate controla 0.84 (0.52–1.36) 0.47 0.57 (0.26–1.25) 0.16 1.00 (0.50–2.00) 0.99
Duration of AF per month 1.01 (1.00–1.01) 0.004 1.03 (1.01–1.04) <0.001
Female sex 1.87 (1.15–3.03) 0.011
NT-proBNP per 100 1.03 (1.01–1.04) 0.001 1.08 (1.03–1.13) <0.001
hsTroponin-T 1.02 (1.01–1.04) 0.003 1.09 (1.04–1.13) <0.001
LAVI (mL/m2) 1.09 (1.05–1.14) <0.001
Duration AF  LAVI 1.00 (0.99–1.00) 0.031
NT-proBNP hsTroponin-T 0.99 (0.99–1.00) 0.016
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; LAVI, left atrial volume index; NT-proBNP, N-terminal proB-type natriuretic peptide.
Men BLSF-36











* * * *



















































Figure 2 Quality of life. Three quality of life (QoL) scores at baseline (BL) and end of study (EoS): (A) the Medical Outcomes Study Short-Form
questionnaire (SF-36), (B) the Multidimensional Fatigue Inventory (MFI-20), and (C) the Toronto AF Severity Scale (AFSS). SF-36 scores range from 0
to 100, with lower scores representing a lower QoL. MFI-20 scores range from 0 to 35, with higher scores indicating greater AF symptom severity.
AFSS score ranges from 4 to 20, with higher scores indicating more fatigue. *P-values <0.05 between the sexes.
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have hypertension, HFpEF, poorer kidney function, and more mitral
regurgitation. This may partially reflect the epidemiologically later age
at AF onset in women and the fact that ageing allows the acquirement
of more risk factors.2–4 Men had more often CAD.4
Risk factors play a prominent role in AF pathophysiology and sex
may modulate how various risk factors contribute to AF.4,14 The
prevalence of major risk factors have changed in both men and
women during the years, and the population attributable risk of AF
risk factors changed too.1,2 Atrial fibrillation risk factors translate into
disease progression; a higher number of risk factors is associated with
a stepwise increase in AF risk and AF progression including poorer
outcomes in patients with metabolic syndrome.4,5 The specific patho-
physiological mechanisms, however, remain incompletely studied.
The presence of more risk factors in women, as demonstrated by
our data, may explain the worse outcome and worse QoL observed.
Women more frequently used rate control drugs, specifically di-
goxin, or digoxin in combination with a beta-blocker. The Euro
Observation Research Programme on Atrial Fibrillation (EORP-AF)
survey also reported more digoxin use in women.2 Prescribed dos-
ages of beta-blockade were higher in women receiving lenient rate
control. Reasons are speculative, but greater symptom burden in
women may prompt treating physicians to prescribe a higher dose.
The higher rates of digoxin use may also reflect poorer tolerability
and/or effect to commonly used rate-control medications.
Additionally, women more often used a diuretic drug. To what extent
sex differences in clinical profile and outcome reflect treatment dis-
parities remains unknown.
Cardiovascular events
Women in RACE II experienced a higher cardiovascular event-rate.
This was caused by a slightly higher, non-significant, occurrence of
nearly all primary endpoint components. After adjustment for the
number of underlying risk factors, however, the difference was no
longer significant. In our cohort matched on sex and risk factors, we
also observed no difference in outcome between women and men,
further supporting the unmatched results. There have been longitudi-
nal studies that reported higher mortality rates,8,9 and higher risk of
stroke and thromboembolism in mostly older women, but results
vary.6,7 Women in RACE II were on average 5 years younger than in
the Framingham Original cohort, and follow-up was shorter.8
Additionally, RACE II patients were treated according to prevailing
ESC AF guidelines at the time of inclusion,12 including oral anticoagu-
lation in nearly all patients. This is contrary to studies that describe
higher stroke and systemic embolisms rates in women.7 We ob-
served a trend towards more extracranial bleeding events in women,
conceivably explained by the fact that women had multiple risk fac-




We describe sex-specific parameters associated with cardiovascular
event occurrence. In women, LAVI and duration of AF were associ-
ated with primary endpoint occurrence. This supports findings of
AFFIRM that described female sex and mitral valve regurgitation be-
ing independently associated with left atrial enlargement,14 and left
atrial enlargement being associated with a higher risk of cardiovascu-
lar death only in women.14 Left atrial enlargement is often an expres-
sion of risk factor and age-related degeneration due to
haemodynamic changes in pressure- and volume load.16 Similarly,
longer AF durations are associated with more severe remodelling,
larger atria and worse outcome.4 Women included in RACE II had
more AF risk factors, possibly partially explaining the link between
LAVI and outcome. However, we cannot exclude a sex difference in
atrial structural remodelling resulting in a more pronounced abnor-
mal atrial milieu. Our findings confirm left atrial size as a marker in
prognosis assessment of AF patients and underscore the clinical rele-
vance of left atrial measurements.16 However, it should be noted that
in AF patients visualization of the left atrium may be suboptimal and
complicated by irregular contractions of the left atrial wall, limiting
the reproducibility of left atrial parameters measures.
In men, NT-proBNP and hsTroponin-T were associated with pri-
mary endpoint occurrence, despite NT-proBNP levels being higher
in women. It is known that women have higher NT-proBNP levels,
regardless of menopause status or hormone therapy, and require
higher cut-offs for optimal sensitivity and specificity in systolic dys-
function detection.17 The independent predictive value of
hsTroponin-T and NT-proBNP for cardiovascular death and throm-
boembolic events in anticoagulated AF patients has been described in
a substudy of the Randomized Evaluation of Long-Term
Anticoagulant Therapy (RE-LY) trial.18 NT-proBNP is a marker of
atrial- and ventricular dysfunction.19 Origin of elevated hsTroponin-T
in AF patients is not completely known, but may be due to mecha-
nisms such as increased and irregular ventricular rate causing oxygen
supply-demand mismatch and subsequent ischaemia, oxidative stress,
and volume and pressure overload.19 The specific role of these blood
biomarkers, which may reflect sex differences in cardiovascular path-
ophysiology, should be investigated further.
Quality of life
Studies indicate that women are more likely to experience symptoms
and a worse QoL.10,20 We report that women experienced mainly
physical limitations during follow-up; no differences in mental status
were observed. Observed differences remained after correcting for
age, heart rate, and risk factors. Additionally, in our matched cohort
similar results were observed. Women continued to experience
more severe physical limitations and reduced activity than men.
Women more often used dual therapy (digoxin and beta-blocker)
and higher dosages of beta-blocker. Higher dosages of beta blockade
may result in more pronounced adverse effects, including fatigue,
negatively affecting women’s physical ability.2 The number of AF risk
factors was associated with a reduced QoL, more clearly in women
than in men, this suggests that women are more negatively affected,
in terms of QoL, by permanent AF.
Limitations and strengths
Present study is a post hoc analysis of RACE II and thus not specifically
designed to study sex differences. Our data are restricted to observa-
tions and cannot reveal (causal) mechanisms. Therefore, the current
study should be interpreted as hypothesis generating since the (path-
ophysiological)processes that underlie the observed sex differences
remain elusive. Furthermore, there is an inherent baseline risk (fac-
tor) difference between men and women which is intertwined with
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the outcome difference observed. This may be bias in enrolment in
the RACE II trial, actual population differences, or both. Therefore,
current population may not be representative of a population-based
sample. Additionally, we adjusted for randomization strategy in our
analyses, but not for the high number of possible combinations of
negative dromotropic drugs and dosages, as this would inappropri-
ately complicate the analyses. The performed propensity score
matching, albeit balancing covariates on average, also has it disadvan-
tages. The matched cohort is smaller, the relative importance of
covariates in their effects on outcome and QoL may differ, and
unmeasured characteristics and confounders remain unbalanced.
Nevertheless, these additional data support our main results.
Data on time in therapeutic range in patients receiving a vitamin K an-
tagonist is missing, and the RACE 2 study was performed in the pre
non-vitamin K oral anticoagulation (NOAC) era. Additionally, follow-up
for cardiovascular events was limited to a relatively short follow-up of 3
years. These factors should be kept in mind when interpreting the
results. Echocardiographic measurements were performed during AF,
which may have influenced measurements, but this was the same for all
patients. Blood markers represent one single-time point, but all patients
were in stable condition and permanent AF at time of blood withdrawal.
Studied risk factors were limited to those pre-specified, and therefore
collected, in RACE II. Women were underrepresented in RACE II, as in
many RCTs. Increasing female participation in RCTs will improve gener-
alizability of trials and allow for effect modification by sex, which is es-
sential to generate adequate evidence in women. Strengths include our
well-characterized cohort, frequent follow-up, and data collection of
events. An independent endpoint committee who were unaware of
assigned treatment strategy adjudicated all endpoints.
Conclusions
Important sex differences exist in patients with permanent AF.
Women were older, had more AF risk factors, and more frequently
used rate control drugs. In women and men different parameters
were associated with events. The observed higher cardiovascular
event rate in women was no longer significant after adjusting for the
number of risk factors. Further, QoL was negatively influenced by the
higher number of risk factors in women. These findings highlight AF
complexity and heterogeneity. More knowledge about sex-specific
differences in AF risk and risk factors is essential to optimize cardio-
vascular care for both men and women.
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Supplementary material is available at Europace online.
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